Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations.

ABSTRACT:

Importance

To our knowledge, little is known about antibody development after SARS-CoV-2 vaccination in immunocompromised individuals, such as patients with cancer.

Objective

To determine whether hematooncological patients develop anti-SARS-CoV-2 antibodies after vaccination.

Design, setting, and participants

This retrospective cohort study included 2 independent cohorts of patients who were treated for hematological and solid malignant tumors between October 2020 and May 2021, comprising 901 samples from 595 patients and 58 health care workers (HCWs). Serum samples were collected from patients who were treated at an academic center and a community hospital in a rural area and a control group of HCWs, all of whom received SARS-CoV-2 vaccination.

Main outcomes and m

SUBMITTER: Mair MJ 

PROVIDER: S-EPMC8485209 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature